| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers A > Headlines for Acrongenomics Inc. > News item |
Acrongenomics, Molecular Vision to combine efforts for point-of-care diagnostics
By Elaine Rigoli
Tampa, Fla., March 29 - Acrongenomics, Inc. and Molecular Vision Ltd., an Imperial Innovations spin-out company, signed a memorandum of understanding Wednesday to develop and commercialize a line of low-cost, portable point-of-care diagnostic devices.
The devices will allow for on-the-spot quantitative/qualitative diagnosis for diabetes, drug abuse, sexually transmitted diseases and cardiovascular diseases, according to a news release.
The ability to perform accurate and fast diagnosis at first consultation will eliminate the need for patients to make repeat visits, thereby bringing forward the initiation of treatment, freeing up clinical time and lowering treatment costs.
The technology offers potential outside the diagnostics market and will be of use to many specialists lacking access to on-site laboratory facilities, the release said.
The global point-of-care testing market is estimated to reach $18 billion by 2010, the release said.
Molecular Vision's patented diagnostic chips are based on a novel technology platform that will allow the development of portable devices for a broad range of medical applications. They incorporate two powerful technologies: microfluidics and organic semiconductor devices (light-emitting diodes and photodetectors).
Acrongenomics, based in Geneva, Switzerland, focuses on investing and commercializing novel technology platforms concerning the life sciences sector.
Molecular Vision, based in London, develops methods for optical detection based on recent advances in organic electronics and light-emitting diodes combined with microfluidics technology.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.